MTOR and Fabry disease: To assess the involvement of mTOR pathway in the pathophysiology of Gaucher and Fabry diseases, PBMCs from patients and healthy controls were treated with rapamycin for 3h because short incubation with rapamycin specifically abolishes mTORC1, but not mTORC2 activity [20–22].